Efficacy and safety of a single oral dose of pilsicainide in supraventricular arrhythmia after coronary artery bypass grafting
Autor: | Takashi Shimabukuro, Takeuchi Y, Naoko Nagano, Akihiko Gomi, Koji Kohno, Yuji Suda, Hayao Nakatani |
---|---|
Rok vydání: | 1998 |
Předmět: |
Male
medicine.medical_specialty Sinus tachycardia Pilsicainide Hemodynamics Postoperative Complications Pharmacokinetics Internal medicine Tachycardia Supraventricular Humans Medicine Sinus rhythm cardiovascular diseases Coronary Artery Bypass Aged Aged 80 and over Supraventricular arrhythmia business.industry Lidocaine Middle Aged Cardiac surgery Blood pressure Anesthesia cardiovascular system Cardiology Female medicine.symptom Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents medicine.drug |
Zdroj: | The Japanese Journal of Thoracic and Cardiovascular Surgery. 46:361-367 |
ISSN: | 1863-2092 1344-4964 |
Popis: | We evaluated the efficacy and safety of administration of a single oral dose of Pilsicainide, a class Ic antiarrhythmic agent, in 34 patients (26 men, 8 women, age from 48 to 81, mean age 66 +/- 8 years) who developed supraventricular arrhythmia after coronary artery bypass grafting (CABG). A total of 42 episodes of postoperative supraventricular arrhythmia, with the majority occurring 2-4 days after CABG, were classified as follows: paroxysmal atrial fibrillation, 34; paroxysmal atrial flutter, 6; and sinus tachycardia, 2. Sinus rhythm was restored in 32 episodes (78%) by treatment with oral pilsicainide given in a single dose of 50 ro 100 mg. Successful conversion was obtained within 90 minutes in 44% and 3 hours in 56% of episodes, with a mean conversion time of 119.2 +/- 107.5 minutes after the administration of pilsicainide. The mean conversion times tended t highlight the difference between the 50 mg and 100 mg doses, but this difference was not statistically significant (p = 0.053). The ventricular rate was significantly reduced from 123.3 +/- 29.5 beats/min to 85.6 +/- 19.9 beats/min (p0.0001), however no significant changes in blood pressure or no significant side effects were observed. The results of the present study suggest that a single oral dose of pilsicainide, administered for its favorable pharmacokinetic profile and lack of hemodynamic side effects, is a valuable drug for converting supraventricular arrhythmia to sinus rhythm in most patients after CABG. |
Databáze: | OpenAIRE |
Externí odkaz: |